A new urine test has demonstrated the ability to detect more than 90 percent of bladder cancers, offering a potential alternative to the invasive cystoscopy procedure currently used for diagnosis. The test, known as Galesas bladder, was evaluated in a trial involving 964 patients within the UK National Health Service (NHS).

The study found that the urine test identified 71 out of 77 cases of bladder cancer, yielding a detection rate of approximately 92 percent. Notably, it detected all cases of muscle-invasive bladder cancer, the most aggressive form of the disease. The test also showed a high specificity, correctly ruling out cancer in 99.3 percent of cases. These findings suggest the test could significantly improve diagnostic accuracy while reducing patient burden.

Currently, patients presenting with symptoms such as blood in the urine, the most common early sign of bladder cancer, are referred for cystoscopy. This procedure involves inserting a thin tube with a camera through the urethra to visually examine the bladder interior. Each year, over 300,000 cystoscopies are performed in the UK, often with patients experiencing lengthy waiting times before the procedure and results.

The researchers, led by the University of Birmingham’s Bladder Cancer Research Centre, estimate that implementing the urine test as an initial screening tool could reduce the need for cystoscopy by approximately 73 percent. This reduction would not only ease pressure on NHS resources but could also expedite diagnosis and improve patient experience.

Bladder cancer affects roughly 11,000 people annually in the UK and causes about 6,000 deaths each year. Symptoms commonly include hematuria (blood in urine) and dysuria (pain while urinating). Early detection remains critical for improving outcomes for patients.

Professor Richard Bryan, director of the University of Birmingham’s Bladder Cancer Research Centre and co-author of the study, described the findings as significant for clinical practice. He emphasized that molecular urine testing could help clinicians decide which patients require urgent cystoscopy and which could safely defer the invasive procedure. He also highlighted the ease of administering the Galesas test compared to cystoscopy.

The results of the study were published in the journal European Urology Oncology, underscoring the promise of molecular diagnostics in the management of bladder cancer. Further research and clinical implementation efforts are likely to follow to confirm the test's role in routine care.